Bora scoops up plant from Eden, the company at the center of the Genentech theft saganews2022-05-13T13:59:10+00:00May 13th, 2022|Fierce Pharma|
Novartis’ Sandoz strikes at Roche with first US generic of blockbuster Esbrietnews2022-05-13T13:34:29+00:00May 13th, 2022|Fierce Pharma|
Mitsubishi Tanabe scores FDA nod for oral version of its ALS drug Radicavanews2022-05-13T13:33:40+00:00May 13th, 2022|Fierce Pharma|
Bristol Myers sells NY biologics plant for $160M to fuel Lotte’s drugmaking ambitionsnews2022-05-13T12:41:57+00:00May 13th, 2022|Fierce Pharma|
FDA halts UCB’s psoriasis drug application over facility inspection issuesnews2022-05-13T12:21:07+00:00May 13th, 2022|Fierce Pharma|
Fierce Pharma Asia—Takeda’s patent cliff and rare disease setback; FDA’s censure of Sun, Aurobindonews2022-05-13T11:41:02+00:00May 13th, 2022|Fierce Pharma|
Amgen finds a dance partner in Lance Bass, urging psoriatic arthritis patients to do a ‘Double Take’ on the diseasenews2022-05-13T08:19:52+00:00May 13th, 2022|Fierce Pharma|
GSK’s ViiV, Horizon and Pfizer earn top scores from U.S. patient groups: surveynews2022-05-12T22:03:56+00:00May 12th, 2022|Fierce Pharma|
Eli Lilly, Novo Nordisk and Sanofi face new lawsuit from Arkansas AG over insulin pricesnews2022-05-12T18:42:19+00:00May 12th, 2022|Fierce Pharma|
Eli Lilly, Novo Nordisk and Sanofi face new lawsuit from Arkansas attorney general over insulin pricesnews2022-05-12T18:42:19+00:00May 12th, 2022|Fierce Pharma|
